ESMO Asia 2023 | Alectinib for the treatment of NSCLC: an update on the ALINA trial

Masahiro Tsuboi, MD, National Cancer Center Hospital East, Chiba, Japan, outlines the randomized, multicenter, Phase III ALINA (NCT03456076) trial studying alectinib versus chemotherapy in patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) in an adjuvant setting. The primary endpoint of disease free survival was met, alectinib providing a significant reduction in both disease recurrence and death. Analysis of an Asian subset aligns with these results. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.